AR122805A1 - HER2 MUTATION INHIBITORS - Google Patents

HER2 MUTATION INHIBITORS

Info

Publication number
AR122805A1
AR122805A1 ARP210101822A ARP210101822A AR122805A1 AR 122805 A1 AR122805 A1 AR 122805A1 AR P210101822 A ARP210101822 A AR P210101822A AR P210101822 A ARP210101822 A AR P210101822A AR 122805 A1 AR122805 A1 AR 122805A1
Authority
AR
Argentina
Prior art keywords
compounds
her2 mutation
salts
mutation inhibitors
enantiomers
Prior art date
Application number
ARP210101822A
Other languages
Spanish (es)
Inventor
Mark Laurence Boys
Bryan Daniel Ellis
John Joseph Gaudino
Erik James Hicken
Ellen Ruth Laird
Nicholas Charles Lazzara
Bradley Jon Newhouse
Spencer Phillip Pajk
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of AR122805A1 publication Critical patent/AR122805A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuestos de la fórmula (1), y enantiómeros de estos, y a sales farmacéuticamente aceptables de la fórmula (1) y dichos enantiómeros, en donde L¹, L², R¹, R², R³ y n son como se definen en el presente documento. Además composiciones farmacéuticas que comprenden dichos compuestos y sales, y métodos y usos de dichos compuestos, sales y composiciones para el tratamiento del crecimiento celular anormal, incluido el cáncer, en un sujeto que lo necesite.Compounds of formula (1), and enantiomers thereof, and pharmaceutically acceptable salts of formula (1) and said enantiomers, wherein L¹, L², R¹, R², R³ and n are as defined herein. Furthermore pharmaceutical compositions comprising said compounds and salts, and methods and uses of said compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

ARP210101822A 2020-06-30 2021-06-29 HER2 MUTATION INHIBITORS AR122805A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063046506P 2020-06-30 2020-06-30

Publications (1)

Publication Number Publication Date
AR122805A1 true AR122805A1 (en) 2022-10-05

Family

ID=83835076

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101822A AR122805A1 (en) 2020-06-30 2021-06-29 HER2 MUTATION INHIBITORS

Country Status (1)

Country Link
AR (1) AR122805A1 (en)

Similar Documents

Publication Publication Date Title
UY38553A (en) CDK2 INHIBITORS
ECSP20067394A (en) CYCLINE-DEPENDENT KINASE INHIBITORS
CL2019000368A1 (en) CDK2 / 4/6 inhibitors.
CO2021017504A2 (en) Benzisoxazole Sulfonamide Derivatives
CL2021001190A1 (en) Azalactam compounds as inhibitors of hpk1
DOP2022000117A (en) KRAS G12C INHIBITORS
UY37900A (en) NEW DERIVATIVES OF RAPAMYCIN
ECSP22033597A (en) SMALL MOLECULE INHIBITORS OF KRAS MUTANT G12C
CO2017009891A2 (en) Inhibitors of transforming growth factor beta inhibitors (tgf-beta)
DOP2024000039A (en) QUINOLINE DERIVATIVES AS ALFA4BETA7 INTEGRIN INHIBITORS
PE20142339A1 (en) MACROCYCLICAL DERIVATIVES FOR THE TREATMENT OF DISEASES
DOP2023000281A (en) HER2 MUTATION INHIBITORS
DOP2023000245A (en) CHROMENONE ALLOSTERIC INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASES
CO2022015448A2 (en) Azalactam compounds as hpk1 inhibitors
UY39517A (en) BTK INHIBITORS
AR122805A1 (en) HER2 MUTATION INHIBITORS
UY39303A (en) HER2 MUTATION INHIBITORS
AR126238A1 (en) HER2 MUTATION INHIBITORS
EA202191818A1 (en) 3-CARBONYLAMINO-5-CYCLOPENTYL-1H-PYRAZOL COMPOUNDS WITH INHIBITING ACTIVITY AGAINST CDK2